Abstract
The G-protein-coupled receptor 55 (GPR55) was identified in 1999. It was proposed as a novel member of the endocannabinoid system due to the fact that some endogenous, plant-derived and synthetic cannabinoid ligands act on GPR55. However, the complexity of the cellular downstream signaling pathways related to GPR55 activation delayed the discovery of selective GPR55 ligands. It was only a few years ago that the high throughput screening of libraries of pharmaceutical companies and governmental organizations allowed to identify selective GPR55 agonists and antagonists. Since then, several GPR55 modulator scaffolds have been reported. The relevance of GPR55 has been explored in diverse physiological and pathological processes revealing its role in inflammation, neuropathic pain, bone physiology, diabetes and cancer. Considering GPR55 as a new promising therapeutic target, there is a clear need for new selective and potent GPR55 modulators. This review will address a current structural update of GPR55 ligands.
Keywords: Agonist, Antagonist, Cannabinoid, Endocannabinoid, GPCR, GPR55, Structure.
Current Medicinal Chemistry
Title:Advances Towards The Discovery of GPR55 Ligands
Volume: 23 Issue: 20
Author(s): Paula Morales and Nadine Jagerovic
Affiliation:
Keywords: Agonist, Antagonist, Cannabinoid, Endocannabinoid, GPCR, GPR55, Structure.
Abstract: The G-protein-coupled receptor 55 (GPR55) was identified in 1999. It was proposed as a novel member of the endocannabinoid system due to the fact that some endogenous, plant-derived and synthetic cannabinoid ligands act on GPR55. However, the complexity of the cellular downstream signaling pathways related to GPR55 activation delayed the discovery of selective GPR55 ligands. It was only a few years ago that the high throughput screening of libraries of pharmaceutical companies and governmental organizations allowed to identify selective GPR55 agonists and antagonists. Since then, several GPR55 modulator scaffolds have been reported. The relevance of GPR55 has been explored in diverse physiological and pathological processes revealing its role in inflammation, neuropathic pain, bone physiology, diabetes and cancer. Considering GPR55 as a new promising therapeutic target, there is a clear need for new selective and potent GPR55 modulators. This review will address a current structural update of GPR55 ligands.
Export Options
About this article
Cite this article as:
Morales Paula and Jagerovic Nadine, Advances Towards The Discovery of GPR55 Ligands, Current Medicinal Chemistry 2016; 23 (20) . https://dx.doi.org/10.2174/0929867323666160425113836
DOI https://dx.doi.org/10.2174/0929867323666160425113836 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Melanocortins As Innovative Drugs for Ischemic Diseases and Neurodegenerative Disorders: Established Data and Perspectives
Current Medicinal Chemistry Experimental Model Considerations for the Study of Protein-Energy Malnutrition Co-Existing with Ischemic Brain Injury
Current Neurovascular Research Glucose Control and Use of Continuous Glucose Monitoring in the Intensive Care Unit: A Critical Review
Current Diabetes Reviews Antihypertensive Treatments in Patients Affected by Aortic Valve Stenosis
Current Pharmaceutical Design Ligands of Diltiazem Binding Site: An Overview of Some Chemotypes
Mini-Reviews in Medicinal Chemistry A Closer Look to Polyesters: Properties, Synthesis, Characterization, and Particle Drug Delivery Applications
Nanoscience & Nanotechnology-Asia Dendrimers and Dendritic Polymers as Anti-infective Agents: New Antimicrobial Strategies for Therapeutic Drugs
Anti-Infective Agents in Medicinal Chemistry Efficacy and Cardiovascular Safety of SGLT2 Inhibitors
Current Drug Safety Safety Limits of Antidepressant Use Plus Combinations: Focus on Cardiovascular Function
Current Drug Metabolism Corticotropin-Releasing Factor Receptor Antagonists in Affective Disorders and Drug Dependence - An Update
CNS & Neurological Disorders - Drug Targets Patent Perspective for Potential Antioxidant Compounds-Rutin and Quercetin
Recent Patents on Nanomedicine Efficacy and Safety of Angiotensin-Converting Enzyme Inhibitors in Combination with Angiotensin-Receptor Blockers in Nondiabetic Chronic Kidney Disease: A Systematic Review and Meta-Analysis
Current Medicinal Chemistry The Role of Venous Abnormalities in Neurological Disease
Reviews on Recent Clinical Trials Inflammation-Mediating Proteases: Structure, Function in (Patho) Physiology and Inhibition
Protein & Peptide Letters Should STEMI Patients Receive Opiate Analgesia? The Morphine Paradox
Current Vascular Pharmacology B-Type Natriuretic Peptide for Diagnosis and Therapy
Recent Patents on Cardiovascular Drug Discovery Phenothiazines as Anti-Multi-Drug Resistant Tubercular Agents
Infectious Disorders - Drug Targets The Oxygen Therapy
Current Medicinal Chemistry Remdesivir and Hydroxychloroquine: A Compassionate Use in Covid-19
Current Drug Targets The Main Receptors Involved in the COVID-19: A Systematic Review and Meta-Analysis
Current Medicinal Chemistry